Results 51 to 60 of about 658 (148)
An update on autophagy disorders
Abstract Macroautophagy is a highly conserved cellular pathway for the degradation and recycling of defective cargo including proteins, organelles, and macromolecular complexes. As autophagy is particularly relevant for cellular homeostasis in post‐mitotic tissues, congenital disorders of autophagy, due to monogenic defects in key autophagy genes ...
Hormos Salimi Dafsari +6 more
wiley +1 more source
A Rare Case of Severe Congenital RYR1‐Associated Myopathy
Congenital myopathies are a group of rare inherited diseases, defined by hypotonia and muscle weakness. We report clinical and genetic characteristics of a male preterm newborn, whose phenotype was characterized by severe hypotonia and hyporeactivity, serious respiratory distress syndrome that required mechanical ventilation, clubfoot, and other ...
Nicola Laforgia +9 more
wiley +1 more source
Additional file 1. Figure S1. Regional heat map of healthcare provider locations for all 192 patients based on the NPI Registry Practice by 5-digit zip code. Table S1. Codes for planned vs unplanned hospitalization.
Graham, Robert J. +6 more
openaire +1 more source
Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Abstract Hepatoxicity associated with recombinant adeno‐associated virus gene therapy is being increasingly encountered by hepatologists in tertiary and quaternary referral units due to the recent increase of these therapies for neuromuscular and haematological disorders.
Barath Jagadisan, Anil Dhawan
wiley +1 more source
Many clinical features of autosomal centronuclear myopathies (CNM) and X-linked myotubular myopathy (XLMTM) are common to congenital myasthenic syndromes (CMS).
Pike, Michael G. +44 more
core +1 more source
Current developments of gene therapy in human diseases
Gene therapy has seen remarkable advancements in recent decades, demonstrating its immense potential in treating a wide range of genetic and acquired diseases. Several AAV gene therapy products have been introduced to the market, addressing various conditions.
Fanfei Liu +4 more
wiley +1 more source
AAV gene replacement therapy for treating MPS IIIC: Facilitating bystander effects via EV‐mRNA cargo
Abstract MPS IIIC is a lysosomal storage disease caused by mutations in heparan‐α‐glucosaminide N‐acetyltransferase (HGSNAT), for which no treatment is available. Because HGSNAT is a trans‐lysosomal‐membrane protein, gene therapy for MPS IIIC needs to transduce as many cells as possible for maximal benefits. All cells continuously release extracellular
Tierra A. Bobo +6 more
wiley +1 more source
Diagnosing X-linked Myotubular Myopathy - A German 20-year Follow Up Experience. [PDF]
peer reviewedX-linked myotubular myopathy (XLMTM) is a life-threatening rare neuromuscular disease, which is caused by pathogenic variants in the MTM1 gene.
Gangfuss, Andrea +13 more
core +1 more source
Hepatitis after gene therapy, what are the possible causes?
Abstract Hepatitis is a common adverse event following gene therapy for haemophilia, often associated with a loss of transgene expression. Investigating the potential causes and implications of this is crucial for the overall success of treatment. Gene therapy trials using adeno‐associated virus (AAV) vectors have demonstrated promising results marked ...
Ann Maina, Graham R. Foster
wiley +1 more source
INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular Myopathy [PDF]
BACKGROUND: X-linked myotubular myopathy (XLMTM) is a life-threatening congenital myopathy that, in most cases, is characterized by profound muscle weakness, respiratory failure, need for mechanical ventilation and gastrostomy feeding, and early death ...
Lee, Jun +86 more
core +2 more sources

